BiotechTube

human allogeneic induced pluripotent stem cell (iPSC)-derived dopaminergic neural progenitor cell injection

Phase 1Recruiting
0 watching 0 views this week💤 Quiet
30
Hype Score

Development Stage

✓
Pre-clinical
2
Phase 1
3
Phase 2
4
Phase 3
5
Approved
Indication / Disease

Parkinson's Disease

Conditions

Parkinson's Disease

Trial Timeline

Aug 5, 2025 → Aug 30, 2029

NCT ID
NCT07080775

About human allogeneic induced pluripotent stem cell (iPSC)-derived dopaminergic neural progenitor cell injection

human allogeneic induced pluripotent stem cell (iPSC)-derived dopaminergic neural progenitor cell injection is a phase 1 stage product being developed by Tiantan Bio for Parkinson's Disease. The current trial status is recruiting. This product is registered under clinical trial identifier NCT07080775. Target conditions include Parkinson's Disease.

Hype Score Breakdown

Clinical
10
Activity
5
Company
7
Novelty
3
Community
2

Clinical Trials (1)

NCT IDPhaseStatus
NCT07080775Phase 1Recruiting

Competing Products

20 competing products in Parkinson's Disease

See all competitors
ProductCompanyStageHype Score
UB-312 + PlaceboVaxxinityPhase 1
25
NAV5001 + DaTscanNavidea BiopharmaceuticalsPhase 3
69
piclozotan + 0.9% sodium chloride (normal saline)Daiichi SankyoPhase 2
52
E2007EisaiPhase 3
77
ARICEPTEisaiPhase 3
77
PerampanelEisaiPhase 3
77
GPI 1485EisaiPhase 2
52
E2007EisaiPhase 3
77
Prior Donepezil 5mg + Prior Donzepezil 10mg + Prior PlaceboEisaiPhase 3
77
perampanel + placeboEisaiPhase 2
52
Lemborexant + placeboEisaiApproved
85
Placebo + E2007 + E2007EisaiPhase 3
77
E2007 + E2007 + E2007EisaiPhase 2
52
E2007EisaiPhase 2
52
E2007EisaiPhase 2
52
E2007EisaiPhase 2
52
2 mg perampanel + 4 mg perampanel + placebo comparatorEisaiPhase 3
77
Istradefylline (KW-6002)Kyowa KirinPhase 2
52
Istradefylline 20 mg or 40 mgKyowa KirinPhase 3
77
Istradefylline (KW-6002)Kyowa KirinPhase 3
77

Other Products from Tiantan Bio

EndostatinPhase 2
49
CN-105Phase 2
49